Blending two bioengineered spider silks to develop cancer targeting spheres.

Area of Science:

• Biomaterials Science
• Biotechnology
• Nanotechnology

Background:

• Bioengineered spider silk offers tunable mechanical properties, biocompatibility, and biodegradability.
• Genetic engineering allows functionalization of silk proteins for specific applications, such as drug delivery.
• Self-assembled silk spheres show potential as carriers for targeted cancer diagnostics and therapy.

Purpose of the Study:

• To investigate the potential of blending two types of functionalized spider silk proteins (MS1 and MS2) for improved drug delivery vehicles.
• To evaluate the characteristics and efficacy of hybrid MS1:MS2 silk spheres compared to MS1 spheres alone.

Main Methods:

• Production and functionalization of MaSp1 (MS1) and MaSp2 (MS2) based bioengineered silk proteins.
• Blending of MS1 and MS2 silks at an 8:2 weight ratio to form self-assembled spheres.
• Characterization of sphere properties (size, size distribution, colloidal stability, production efficiency) and assessment of cell binding and drug-induced cytotoxicity.

Main Results:

• The 8:2 MS1:MS2 blend formed spheres with improved size, size distribution, colloidal stability, and production efficiency compared to MS1 spheres.
• MS1:MS2 spheres exhibited equivalent target cell binding as MS1 spheres.
• Drug-loaded MS1:MS2 spheres demonstrated efficient targeted cancer cell killing with significantly lower non-specific toxicity.

Conclusions:

• Blending functionalized spider silk proteins is an advantageous strategy to combine desirable properties from different silk types.
• Hybrid MS1:MS2 silk spheres represent a promising, optimized drug delivery vehicle for targeted cancer therapy.
• This approach enhances therapeutic efficacy while minimizing off-target side effects.